journal
zhu
et
al
recent
report
result
genom
analysi
multidrugresist
klebsiella
pneumonia
isol
individu
patient
colistin
treatment
highlight
rapid
emerg
multifacet
molecular
mechan
colistin
resist
k
pneumonia
work
highlight
therapeut
publichealth
challeng
colistinresist
cr
increasingli
use
larg
resort
antibiot
despit
unattract
toxic
profil
narrow
therapeut
window
oral
nonabsorb
colistin
propos
decontamin
strategi
intens
care
unit
patient
carri
multidrug
resist
enterobacteral
mdre
impact
decolon
strategi
term
emerg
cr
rare
monitor
reliabl
select
medium
exist
cr
consid
publichealth
problem
recent
reliabl
univers
cultur
media
develop
screen
cr
studi
impact
nonabsorb
oral
colistin
emerg
cr
gut
microbiota
patient
random
control
trial
thirtynin
subject
colon
mdre
random
receiv
oral
colistin
sulfat
miu
time
day
neomycin
sulfat
mg
bid
day
follow
fecal
microbiota
transplant
fmt
healthi
donor
intervent
stool
sampl
collect
visit
screen
sampl
day
oral
decontamin
fmt
intervent
group
respect
day
day
day
later
stool
sampl
donor
subject
intervent
group
control
group
avail
work
plate
drigalski
plate
control
superpolymyxin
r
plate
coloni
form
unit
cfu
count
gramneg
rod
determin
isol
grow
superpolymyxin
r
plate
identifi
malditof
cr
confirm
culturebas
rapid
polymyxin
np
test
mic
determin
microdilut
method
limit
detect
cfug
stool
cre
coli
sequenc
use
illumina
hiseq
technolog
determin
whether
cr
isol
present
intervent
specif
pcr
perform
patient
stool
prior
intervent
donor
stool
electropor
plasmid
perform
local
gene
confer
resist
colistin
neomycin
molecular
type
electropor
perform
use
pcr
base
replicon
type
pbrt
de
pari
iam
inserm
patient
donor
includ
trial
carri
cr
isol
among
patient
intervent
group
two
p
carri
cr
isol
least
one
visit
intervent
fig
crenterobacteral
detect
stool
subject
control
group
among
subject
crenterobacteral
one
carri
log
cfug
hafnia
paralvei
speci
intrins
resist
colistin
mic
mgl
also
resist
neomycin
mic
mgl
visit
carri
log
cfug
log
cfug
cre
coli
visit
respect
colistin
mic
mgl
rel
abund
cre
coli
increas
total
enterobacteral
popul
cre
coli
recov
belong
phylogroup
c
group
carri
serotyp
plasmidborn
gene
encod
cr
well
aph
ia
gene
confer
resist
neomycin
identifi
coloc
plasmid
addit
resist
gene
confer
resist
hygromycin
b
aph
ia
sulfonamid
tetracyclin
tet
phenicol
flor
antibiot
use
veterinari
medicin
evidenc
subject
cr
strain
could
retriev
initi
stool
subject
donor
stool
pcr
experi
perform
specif
primer
detect
gene
directli
pretherapeut
stool
also
neg
knowledg
first
report
invivo
select
crenterobacteral
gut
microbiota
patient
oral
decontamin
colistin
select
cr
strain
naturallyresist
h
paralvei
produc
e
coli
resist
colistin
neomycin
may
result
either
enrich
process
sod
preexist
cr
strain
initi
detect
low
abund
exogen
acquisit
either
individu
fmt
inde
transmiss
fmt
mdr
strain
posit
donor
potenti
risk
despit
effort
decreas
limit
detect
mcr
produc
use
pcr
techniqu
directli
pretherapeut
stool
sampl
donor
stool
fail
detect
parent
strain
either
cr
strain
intestin
nich
limit
detect
remain
high
strain
acquir
exogen
howev
posit
e
coli
like
anim
origin
accord
genet
featur
coresist
profil
inde
phylogroup
frequent
encount
among
avian
pathogen
e
coli
apec
coresist
mani
antibiot
use
specif
veterinari
medicin
strike
furthermor
aph
ia
gene
confer
resist
neomycin
paromomycin
latter
commonli
use
cattl
pig
select
produc
illustr
one
health
problem
resist
strain
like
select
veterinari
antibiot
among
anim
end
patient
gut
later
enrich
use
colistin
neomycin
decontamin
although
small
number
subject
clear
limit
observ
proofofconcept
risk
select
crenterobacteral
oral
colistin
treatment
fmt
time
colistin
one
last
resort
antibiot
treat
mdrenterobacteral
infect
select
commens
cre
coli
especi
worri
given
pathogen
potenti
e
coli
abil
wide
colon
anim
human
given
controversi
result
oral
decontamin
colistin
believ
use
precaut
thorough
monitor
cr
read
interest
recent
paper
journal
luzatti
colleagu
explor
signific
presenc
herp
simplex
viru
hsv
dna
lower
respiratori
tract
lrt
specimen
diagnosi
hsv
pneumonia
immunocompromis
patient
author
underlin
difficulti
gaug
clinic
relev
laboratori
find
absenc
histopatholog
data
hsv
shed
lrt
may
occur
absenc
diseas
interpret
realtim
pcr
result
diagnosi
pneumocysti
jirovecii
pj
pneumonia
pjp
face
analog
challeng
sinc
presenc
pj
dna
lrt
may
reflect
colon
carriag
rather
infect
limit
inform
clinic
valu
pj
realtim
pcr
diagnos
pjp
patient
hematolog
diseas
exceedingli
challeng
sensit
direct
examin
procedur
suboptim
due
low
fungal
burden
report
experi
matter
total
episod
pneumonia
occur
consecut
patient
hematolog
disord
pjp
consid
differenti
etiolog
diagnosi
includ
episod
develop
patient
undergo
either
allogen
hematopoiet
stem
cell
transplantationallohsct
n
autologoushsct
n
nontranspl
patient
acut
leukemia
n
lymphoma
n
chronic
leukemia
n
other
n
patient
attend
hospit
universitariohcu
n
hospit
universitario
la
fe
hlf
n
june
august
patient
cohort
test
posit
hiv
studi
approv
respect
hospit
ethic
committe
inform
consent
obtain
patient
singl
specimen
per
episod
avail
diagnosi
bal
fluid
n
sputa
n
ta
n
bronchial
biopsi
n
realcycl
pjir
kit
r
progeni
molecular
spain
use
hcu
pneumocysti
jirovecii
real
time
pcr
detect
certest
biotech
zaragoza
spain
employ
hlf
see
footnot
tabl
assay
target
larg
subunit
ribosom
mtlsu
rna
gene
preliminari
experi
use
bal
specimen
indic
assay
yield
compar
pcr
cycl
threshold
c
median
rang
vs
median
rang
respect
p
specimen
test
neg
direct
examin
pj
wherea
posit
realtim
pcr
bal
n
sputa
n
ta
n
follow
stringent
clinic
microbiolog
imag
criteria
tabl
pjp
deem
probabl
diagnosi
episod
occur
uniqu
patient
histopatholog
confirm
pjp
avail
patient
pcr
c
valu
invers
correl
fungal
burden
sampl
higher
patient
pjp
colon
individu
overal
pj
pcr
c
specimen
patient
pjp
tend
lower
pj
carrier
p
bal
fluid
specimen
consid
differ
reach
statist
signific
median
rang
vs
median
rang
p
find
like
relat
use
standard
procedur
bal
fluid
sampl
receiv
oper
characterist
roc
curv
analysi
show
threshold
c
valu
bal
specimen
display
sensit
ci
specif
ci
pjp
diagnosi
number
studi
establish
differ
c
cutoff
purpos
view
howev
variabl
perform
differ
pcr
assay
sampl
condit
heterogen
patient
popul
particular
lack
pj
intern
standard
materi
pcr
result
normal
preclud
defin
consensu
univers
threshold
nowaday
absenc
antipj
prophylaxi
treatment
corticosteroid
serum
ldh
level
ul
shown
associ
pjp
patient
undergo
antipj
prophylaxi
like
display
clinic
signific
pj
pcr
result
tabl
turn
roc
curv
analysi
indic
cutoff
ldh
valu
ul
sensit
ci
specif
ci
pjp
diagnosi
univari
regress
logist
model
serum
ldh
valu
ul
associ
clinic
signific
posit
pcr
pj
result
ci
p
contrast
corticosteroid
use
within
month
sampl
differ
probabl
pneumocysti
jirovecii
pj
pneumonia
pjp
patient
retrospect
evalu
expert
committe
includ
infecti
diseas
microbiolog
specialist
center
basi
document
pj
presenc
respiratori
specimen
microscopi
ii
compat
clinic
sign
symptom
least
follow
subtl
onset
progress
dyspnea
pyrexia
nonproduct
cough
hypoxaemia
chest
pain
iii
compat
suggest
radiolog
find
chest
radiograph
andor
highresolut
comput
tomograph
scan
detect
interstiti
opac
andor
diffus
infiltr
infiltr
iv
complet
resolut
symptom
full
cours
antipjp
treatment
v
absenc
altern
diagnosi
efficaci
therapi
assess
daili
basi
pjp
rule
realtim
pcr
pj
test
neg
clinic
recoveri
occur
absenc
pjtarget
antimicrobi
therapi
pj
colon
carriag
like
possibl
patient
meet
criteria
altern
diagnosi
made
b
frequenc
compar
use
test
fisher
exact
test
categor
variabl
twosid
exact
p
valu
report
p
valu
consid
statist
signific
data
analyz
spss
version
statist
packag
c
respiratori
tract
specimen
obtain
follow
convent
procedur
specimen
examin
presenc
ascu
trophic
form
pj
microscopi
follow
blue
toluidin
calcofluor
white
grocott
methenamin
silver
stain
cytospin
prepar
prepar
bal
specimen
direct
examin
sputa
ta
sampl
mix
vv
sputasol
oxoid
uk
vortex
min
sampl
centrifug
g
min
pellet
resuspend
nacl
process
realtim
pcr
dna
extract
specimen
use
qiaamp
dna
blood
mini
kit
qiagen
hilden
germani
either
qia
symphoni
platform
qiagen
follow
manufactur
instruct
hcu
commerciallyavail
realtim
pcr
assay
previous
evalu
other
realcycl
pjir
kit
r
progeni
molecular
spain
target
mitochondri
larg
subunit
ribosom
mtlsu
rna
gene
use
accord
manufactur
instruct
http
wwwprogeniemolecularcompjiruinpdf
hlf
commerciallyavail
pneumocysti
jirovecii
real
time
pcr
detect
certest
biotech
zaragoza
spain
also
target
larg
subunit
ribosom
mtlsu
rna
gene
employ
follow
manufactur
instruct
http
wwwcertest
real
time
pcr
pneumocysti
jirovecii
center
pcr
perform
appli
biosystem
fast
realtim
pcr
platform
appli
biosystem
ca
usa
pcr
result
report
posit
neg
posit
sampl
threshold
cycl
c
valu
also
record
standard
curv
gener
posit
control
quantit
estim
antimicrobi
prophylaxi
pjp
perform
trimethoprimsulfamethoxazol
tmpsmx
one
doublestrength
tablet
mg
mg
smx
given
allogen
hsct
patient
time
week
oral
folic
acid
patient
suspicion
pjp
accord
attend
physician
treat
tmpsmx
mgkg
tmp
mgkg
smx
per
day
week
e
case
death
attribut
pjp
patient
clinic
signific
pj
detect
pj
carrier
tabl
detect
recoveri
microbi
agent
one
document
specimen
test
posit
pj
pcr
tabl
line
previou
report
microbiolog
find
significantli
less
frequent
p
specimen
patient
pjp
colon
patient
fact
microbi
codetect
invers
associ
pjp
univari
logist
regress
model
ci
p
strength
current
studi
follow
clinic
categor
pjp
base
upon
stringent
criteria
defin
multidisciplinari
team
ii
hematolog
patient
includ
iii
comprehens
routin
investig
microbi
caus
pneumonia
pj
conduct
iv
experi
two
center
collect
addit
retrospect
natur
studi
also
limit
complet
rule
patient
categor
pj
carrier
fact
pjp
patient
receiv
full
cours
tmpsmx
combin
antimicrobi
target
microbi
agent
lack
standard
criteria
pjp
diagnosi
make
clinic
misclassif
patient
potenti
drawback
studi
particularli
posit
microscopi
histopatholog
find
avail
ii
although
evalu
bal
bronchoalveolar
lavag
pjp
pneumocysi
jirovecii
pneumonia
ta
tracheal
aspir
per
routin
protocol
specimen
examin
gram
acidfast
bacilli
stain
sampl
also
examin
presenc
respiratori
virus
rv
use
either
luminex
xtag
rvp
fast
assay
luminex
molecular
diagnost
austin
tx
usa
hcu
pneumovir
assay
genomica
coslada
spain
center
previous
report
semiquantit
sputa
quantit
bal
ta
cultur
bacteria
perform
convent
media
bacteri
load
cfuml
cfuml
deem
clinic
relev
bal
fluid
ta
sampl
respect
specimen
cultur
bcyealpha
agar
bd
becton
dickinson
mycobacteria
growth
indic
tube
lowensteinjensen
agar
slant
sabouraud
agar
recoveri
legionella
pneumophila
mycobacterium
spp
fungal
organ
respect
platelia
tm
aspergillu
ag
kit
biorad
hercul
ca
usa
use
quantit
aspergillu
spp
galactomannan
bal
fluid
serum
specimen
bal
fluid
specimen
underw
cytomegaloviru
cmv
pcr
test
use
realtim
cmv
pcr
assay
abbott
molecular
hcu
cmv
assay
biomerieux
hlf
previous
report
patient
presumpt
pjp
iii
two
differ
commerciallyavail
pcr
assay
use
across
center
nevertheless
found
yield
rather
compar
c
summari
found
posit
pj
pcr
result
respiratori
specimen
transplant
nontranspl
hematolog
patient
pneumonia
frequent
reflect
colon
rather
infect
pcr
c
valu
bal
fluid
serum
ldh
level
lack
codetect
microorgan
potenti
involv
may
help
clinic
categor
absenc
posit
pj
microcopi
result
conflict
interest
declar
dear
editor
poller
et
al
journal
provid
use
consensu
use
person
protect
equip
manag
high
consequ
infecti
diseas
although
driven
larg
recent
ebola
viru
diseas
emerg
remind
reader
continu
problem
lassa
fever
lf
west
africa
lf
febril
infecti
diseas
caus
lassa
viru
clinic
present
diseas
nonspecif
includ
fever
fatigu
hemorrhag
gastrointestin
symptom
respiratori
symptom
neurolog
symptom
observ
case
fatal
rate
among
patient
hospit
sever
lf
diseas
mainli
spread
human
contamin
urin
faec
infect
rat
humantohuman
transmiss
occur
contact
bodi
fluid
infect
person
therefor
health
care
worker
high
risk
infect
standard
precaut
infect
prevent
control
includ
appropri
person
protect
equip
inadequ
estim
approxim
lf
case
annual
result
approxim
death
west
african
countri
nigeria
larg
lf
outbreak
previous
report
epidemiolog
characterist
outbreak
analyz
data
collect
januari
may
howev
inform
laboratoryneg
suspect
case
enough
conduct
casecontrol
studi
fulli
determin
risk
factor
clinic
characterist
diseas
nigeria
lf
outbreak
well
report
epidemiolog
clinic
characterist
outbreak
includ
casecontrol
analysi
laboratoryneg
suspect
case
use
data
collect
januari
octob
januari
decemb
suspect
case
includ
laboratoryconfirm
lf
case
suspect
case
report
octob
includ
laboratoryconfirm
lf
case
detail
case
definit
laboratori
test
surveil
data
collect
describ
previous
confirm
lf
case
fatal
case
fatal
rate
fatal
case
fatal
rate
number
laboratoryconfirm
lf
case
posit
rate
peak
dri
season
januarymarch
fig
largest
number
laboratoryconfirm
lf
case
report
neighbor
edo
ondo
state
fig
b
laboratoryconfirm
lf
case
state
kebbi
zamfara
report
case
previous
studi
period
detail
demograph
clinic
inform
collect
laboratoryconfirm
lf
case
case
laboratoryneg
suspect
case
case
chisquar
test
conduct
compar
distribut
age
sex
symptom
laboratoryconfirm
lf
case
laboratoryneg
suspect
case
tabl
proport
children
significantli
lower
laboratoryconfirm
lf
case
compar
laboratoryneg
suspect
case
proport
male
significantli
higher
laboratoryconfirm
lf
case
laboratoryneg
suspect
case
fever
preval
symptom
laboratoryconfirm
lf
case
laboratoryneg
suspect
case
follow
headach
tabl
gastrointestin
symptom
abdomin
pain
vomit
diarrhea
observ
laboratoryconfirm
lf
case
wherea
hemorrhag
observ
laboratoryconfirm
lf
case
preval
faceneck
edema
low
even
laboratoryconfirm
lf
case
nonetheless
odd
ratio
faceneck
edema
time
high
laboratoryconfirm
lf
case
report
lf
outbreak
largest
record
histori
previou
studi
focus
laboratoryconfirm
lf
case
mainli
compar
fatal
case
surviv
case
observ
reveal
differ
laboratoryconfirm
lf
case
laboratoryneg
suspect
case
age
sex
distribut
differ
significantli
laboratoryconfirm
lf
case
laboratoryneg
suspect
case
fever
headach
gastrointestin
symptom
common
symptom
laboratoryconfirm
lf
case
similar
report
previous
howev
symptom
also
preval
laboratoryneg
suspect
case
clinic
guidelin
lf
state
edema
face
neck
specif
sign
diseas
present
studi
found
symptom
significantli
high
odd
ratio
confirm
lf
although
preval
symptom
low
unfortun
determin
differenti
diagnosi
laboratoryneg
suspect
case
laboratori
test
differenti
diagnos
underway
lfneg
sampl
collect
outbreak
result
would
provid
us
insight
better
clinic
manag
patient
febril
ill
lfendem
area
addit
standard
precaut
infect
prevent
control
includ
appropri
person
protect
equip
point
poller
et
al
import
know
epidemiolog
clinic
characterist
high
consequ
infecti
diseas
lf
would
help
healthcar
worker
public
health
offic
increas
index
suspicion
diseas
lead
better
clinic
manag
surveil
author
declar
conflict
interest
exist
work
partial
support
lead
initi
excel
young
research
ministri
educ
cultur
sport
scienc
technolog
japan
japan
societi
promot
scienc
grant
number
funder
role
studi
design
data
collect
analysi
decis
publish
prepar
manuscript
author
contribut
equal
articl
accept
decemb
avail
onlin
januari
http
british
infect
associ
publish
elsevi
ltd
right
reserv
recent
sever
studi
journal
demonstr
threat
animalderiv
virus
human
sinc
increas
human
pseudorabi
viru
prv
infect
case
report
china
indic
new
animalderiv
viru
threat
human
health
porcin
pseudorabi
pr
also
known
aujeszki
diseas
one
econom
import
viral
diseas
pig
global
caus
agent
prv
classifi
genu
varicelloviru
subfamili
alphaherpesvirina
famili
herpesvirida
prv
almost
alway
fatal
newborn
piglet
frequent
accompani
neurolog
symptom
may
caus
abort
andor
stillbirth
pregnant
sow
prv
primarili
infect
member
suida
famili
also
infect
domest
wild
mammal
includ
hors
cattl
sheep
goat
dog
cat
etc
current
vaccin
effect
strategi
pr
prevent
control
pig
worldwid
china
prv
infect
pig
first
record
inactiv
vaccin
consist
vaccin
strain
import
china
sinc
vaccin
wide
use
pig
vaccin
pr
prevent
control
larg
pr
outbreak
report
pig
china
howev
late
novel
prv
wildtyp
variant
emerg
nearli
region
china
affect
number
swine
herd
vaccin
regularli
vaccin
result
signific
econom
loss
subsequ
anim
experi
indic
vaccin
could
provid
complet
protect
pig
challeng
novel
prv
wildtyp
variant
china
control
erad
pr
diseas
list
midand
longterm
anim
diseas
prevent
control
program
china
chines
govern
aim
elimin
pr
china
http
howev
vaccin
prv
still
voluntari
requir
china
nationwid
epidemiolog
investig
demonstr
high
preval
prv
among
swine
herd
china
human
previous
regard
refractori
prv
infect
although
serolog
prv
antibodi
posit
found
three
case
first
human
prv
infect
case
direct
molecular
evid
report
china
case
tabl
case
eye
woman
directli
expos
sewag
hog
farm
follow
two
week
symptom
fever
headach
coma
endophthalm
observ
patient
nextgener
sequenc
ng
indic
prv
dna
detect
vitreou
humor
sampl
cerebrospin
fluid
csf
surgeri
patient
discharg
vision
remain
impair
subsequ
studi
zhao
et
al
tabl
clinic
characterist
inform
twelv
human
prv
infect
case
china
analyz
csf
sampl
four
patient
enceph
unknown
etiolog
use
ng
case
tabl
found
molecular
evid
prv
infect
addit
retin
blind
observ
two
case
case
tabl
patient
case
die
occup
four
patient
associ
pork
productionsalecook
six
human
prv
infect
case
involv
enceph
report
china
patient
porkpig
handler
veterinarian
note
patient
still
suffer
variou
sequela
discharg
except
one
case
patient
die
increas
report
human
prv
infect
case
china
recent
indic
prv
pose
signific
threat
public
health
china
especi
peopl
close
contact
sick
pig
andor
relat
pork
productscontamin
reduc
risk
prv
infect
suscept
worker
necessari
promulg
relev
polici
chines
govern
promot
pr
vaccin
develop
protect
pig
infect
novel
prv
wildtyp
variant
current
circul
china
addit
relev
polici
updat
chines
govern
monitor
vaccin
statu
viru
variat
pig
nationwid
moreov
seem
prv
infect
human
via
injuri
skin
eye
effect
drug
prevent
progress
diseas
caus
prv
infect
report
therefor
necessari
improv
biosafeti
selfprotect
awar
suscept
popul
contact
sick
pig
work
job
relat
handl
pork
productscontamin
promot
drug
develop
cure
prvrelat
diseas
infect
patient
may
also
help
reduc
current
increas
threat
prv
human
health
china
author
declar
compet
interest
dear
editor
emerg
spread
gramneg
bacteria
exampl
klebsiella
pneumonia
coproduc
carbapenemas
mobil
colistin
resist
mcr
gene
limit
choic
treat
multidrugresist
infect
pose
signific
threat
public
health
herein
report
discoveri
gene
k
pneumonia
strain
isol
patient
eight
european
countri
includ
belgium
n
denmark
n
montenegro
n
poland
n
romania
n
serbia
n
slovenia
n
spain
n
notabl
coexist
carbapenemaseencod
gene
confirm
k
pneumonia
isol
human
origin
phylogenet
analysi
suggest
carri
k
pneumonia
isol
includ
carbapenemresist
five
suscept
k
pneumonia
strain
show
highli
geograph
cluster
pattern
genet
environ
analysi
reveal
presenc
insert
element
cupin
fold
metalloprotein
wbuc
flank
taken
togeth
find
indic
exist
long
time
alreadi
spread
among
crkp
isol
human
origin
europ
sinc
increas
signific
threat
public
health
either
nosocomi
spread
environment
rout
mobil
colistin
resist
mcr
gene
detect
human
gut
microbiom
dissemin
across
three
contin
includ
asia
europ
america
recent
publish
journal
infect
rapid
increas
carbapenem
resist
among
gramneg
bacteria
worldwid
greatli
compromis
efficaci
carbapenem
antibiot
gotten
renew
attent
import
polymyxin
antibiot
multidrugresist
mdr
infect
recent
sophia
david
colleagu
report
epidem
carbapenemresist
klebsiella
pneumonia
crkp
europ
rais
concern
mobil
carbapenemas
resist
determin
wide
spread
european
hospit
set
interhospit
spread
far
frequent
within
rather
countri
howev
limit
inform
regard
cooccurr
carbapenemas
mcr
gene
klebsiella
pneumonia
k
pneumonia
isol
provid
plasmidmedi
resist
gene
mcr
well
tet
widespread
bacteri
speci
anim
human
environ
origin
well
human
anim
gut
microbiom
worldwid
huge
arg
reservoir
high
horizont
gene
transfer
possibl
sever
studi
illustr
newli
describ
spread
beyond
unit
state
europ
asia
enterobacteriacea
speci
clinic
concern
inevit
spread
plasmid
harbor
gene
crkp
isol
list
world
health
organ
critic
prioriti
antibioticresist
bacteri
pathogen
new
antibiot
urgent
need
respons
potenti
clinic
problem
download
k
pneumonia
genom
isol
hospit
european
countri
complet
bacteri
genom
sequenc
access
juli
explor
distribut
plasmidmedi
resist
gene
mcr
tet
surpris
find
complet
gene
nucleotid
present
k
pneumonia
isol
k
pneumonia
strain
belgium
n
denmark
n
montenegro
n
poland
n
romania
n
serbia
n
slovenia
n
spain
n
tabl
addit
k
pneumonia
isol
human
origin
crkp
strain
five
carbapenemsuscept
isol
tabl
report
harbour
strain
isol
patient
europ
result
suggest
gene
might
present
europ
long
time
alreadi
spread
crkp
isol
major
caus
hospitaland
communityacquir
infect
analyz
posit
k
pneumonia
isol
resistom
draft
genom
analyz
use
comprehens
antibiot
resist
databas
interestingli
gene
coexist
variou
carbapenemaseencod
gene
eleven
isol
eight
two
fig
note
isol
distribut
denmark
n
montenegro
n
romania
n
serbia
n
well
sever
betalactam
resist
determin
exampl
fig
tabl
moreov
isol
domin
spain
n
slovenia
n
well
two
betalactamaseencod
gene
noncarbapenemas
fig
tabl
worri
crkp
isol
spain
carri
gene
simultan
presenc
crkp
isol
patient
critic
import
could
present
hospitalborn
outbreak
cre
strain
futur
wholegenom
shotgun
wg
data
posit
k
pneumonia
isol
sequenc
type
st
extract
assign
nine
differ
type
ie
fig
phylogenet
analysi
suggest
carri
k
pneumonia
isol
show
highli
geograph
cluster
pattern
fig
isol
patient
hospit
cluster
one
clade
exampl
spain
montenegro
overal
k
pneumonia
isol
differ
countri
genet
divers
suggest
posit
k
pneumonia
isol
also
genet
divers
could
dissemin
among
differ
k
pneumonia
isol
mainli
nosocomi
transmiss
nowaday
known
mcr
gene
detect
variou
gramneg
bacteri
speci
wherea
small
number
studi
shown
presenc
k
pneumonia
isol
anim
human
origin
rel
low
detect
rate
presenc
crkp
isol
indic
novel
mcr
gene
may
alreadi
wide
spread
among
k
pneumonia
isol
human
origin
europ
subsequ
search
gene
complet
bacteri
genom
sequenc
ncbinr
databas
octob
ncbi
fulli
understand
preval
gene
klebsiella
speci
isol
interestingli
gene
ident
queri
coverag
present
variou
bacteri
genom
includ
three
klebsiella
speci
isol
consist
k
pneumonia
n
k
quasipneumonia
n
k
oxytoca
n
tabl
therefor
studi
focus
epidemiolog
transmiss
mechan
mcr
gene
particular
klebsiella
speci
human
origin
warrant
better
understand
public
health
threat
emerg
antibiot
resist
among
clinic
k
pneumonia
contig
carri
k
pneumonia
isol
could
classifi
two
group
exampl
tabl
genet
environ
analysi
indic
presenc
insert
element
wbuc
cupin
fold
metalloprotein
kb
upstream
downstream
flank
respect
similar
ident
plasmid
sequenc
contig
e
coli
isol
salmonella
fig
b
addit
anoth
contig
kb
upstream
two
insert
element
well
betalactamaseencod
resist
gene
similar
plasmid
sequenc
detect
downstream
regulatori
gene
qsec
qseb
found
isol
harbor
moreov
unabl
determin
whether
complet
element
upstream
due
short
bear
contig
avail
comparison
fig
b
therefor
longread
sequenc
coupl
hybrid
assembl
method
need
fulli
evalu
monitor
transfer
develop
arg
especi
among
crkp
isol
although
two
uniqu
plasmidmedi
tigecyclin
resist
gene
firstli
discov
bacteria
anim
origin
china
subsequ
identifi
mani
bacteri
isol
human
anim
environ
origin
includ
klebsiella
speci
well
human
anim
gut
microbiom
none
detect
k
pneumonia
strain
europ
summari
report
discoveri
gene
clinic
k
pneumonia
strain
human
origin
eight
european
countri
importantli
gene
coexist
differ
carbapenemaseencod
gene
strain
spread
betalactam
resist
determin
noncarbapenemas
carri
crkp
appear
like
plasmid
dissemin
gene
identifi
isol
belong
divers
set
st
distribut
differ
hospit
europ
noteworthi
posit
crkp
strain
isol
highlight
earlier
presenc
among
crkp
around
world
previous
known
find
rais
likelihood
ongo
undetect
gene
spread
among
cre
strain
therefor
studi
urgent
need
understand
preval
dissemin
especi
cre
crkp
strain
effect
measur
taken
control
spread
gfg
design
studi
ynw
fl
collect
download
dataset
ynw
fl
yfh
blz
gpz
gfg
analyz
interpret
data
ynw
gfg
wrote
draft
manuscript
author
discuss
review
approv
final
report
supplementari
inform
avail
paper
correspond
request
materi
address
gfg
author
declar
compet
interest
interest
systemat
review
aminchowdhuri
colleagu
provid
inform
outbreak
sever
pneumococc
diseas
spd
close
set
occur
conjug
vaccin
era
show
vaccinetyp
spd
outbreak
still
occur
highlight
lack
consensu
manag
outbreak
follow
describ
manag
recent
outbreak
spd
norway
march
romsdal
hospit
trust
notifi
norwegian
institut
public
health
niph
cluster
spd
amongst
men
work
shipyard
romsdal
counti
serotyp
data
niph
avail
nine
case
serotyp
major
case
work
one
specif
shipyard
municip
medic
offic
mmo
norwegian
labour
inspect
author
nlia
niph
form
multidisciplinari
outbreak
team
investig
control
outbreak
form
specif
case
definit
case
resid
romsdal
counti
period
januari
onward
confirm
invas
pneumococc
diseas
ipd
serotyp
isol
normal
steril
site
probabl
work
specif
shipyard
clinic
present
compat
lower
respiratori
tract
infect
ipd
without
microbiolog
confirm
serotyp
isol
nonsteril
medium
eg
nasopharyng
swab
sputum
cultur
identifi
case
ten
confirm
ten
probabl
period
januari
april
fig
avail
isol
serotyp
confirm
probabl
suscept
penicillin
fifteen
isol
sequenc
type
st
two
singl
locu
variant
st
case
men
year
mean
age
year
fifteen
hospit
four
norwegian
citizen
remain
came
european
countri
seven
case
smoke
one
case
underli
medic
risk
condit
immun
histori
pneumococci
unknown
case
sever
profess
mostli
relat
interior
outfit
metal
weld
approxim
individu
work
shipyard
time
period
mani
live
temporari
accommod
onsit
inspect
shipyard
nlia
observ
pollut
atmospher
work
environ
littl
use
person
protect
equip
sever
measur
put
place
control
outbreak
includ
inform
advic
rais
symptom
awar
reinforc
hand
respiratori
hygien
vaccin
occup
correct
local
medic
clinic
hospit
alert
outbreak
advis
low
threshold
admit
treat
suspect
case
mmo
held
inform
meet
shift
leader
written
inform
spd
sever
languag
distribut
worker
increas
spd
awar
intensifi
hygien
measur
implement
ship
yard
hous
quarter
nlia
order
immedi
occup
correct
relat
control
atmospher
work
environ
niph
recommend
vaccin
conjug
vaccin
interrupt
transmiss
prevent
diseas
polysaccharid
vaccin
provid
protect
serotyp
prefer
may
also
affect
colon
sever
work
task
conduct
parallel
process
confin
space
suboptim
ventil
unabl
identifi
singl
target
group
vaccin
henc
shipyard
offer
vaccin
worker
occup
health
servic
promptli
vaccin
worker
fourday
period
contrari
major
studi
includ
systemat
review
niph
recommend
chemoprophylaxi
worker
otherwis
healthi
ie
high
risk
group
like
old
age
immunocompromis
condit
etc
sinc
imposs
target
specif
group
worker
niph
deem
undesir
distribut
antibiot
asymptomat
worker
possibl
induc
antimicrobi
resist
possibl
side
effect
due
high
turnov
personnel
possibl
calcul
attack
rate
find
new
case
control
measur
implement
death
report
relat
outbreak
outbreak
close
resembl
one
outbreak
describ
systemat
review
april
june
outbreak
serotyp
st
occur
shipyard
belfast
also
awar
outbreak
fall
shipyard
finland
serotyp
st
although
welder
known
risk
group
spd
three
outbreak
peopl
work
close
alongsid
welder
also
infect
addit
exposur
weld
fume
cram
poorli
ventil
work
condit
possibl
hous
condit
may
increas
risk
develop
spd
facilit
transmiss
pneumococci
close
set
overal
norwegian
outbreak
extend
knowledg
manag
control
outbreak
spd
close
set
none
journal
brunet
colleagu
discuss
reactiv
latent
infect
context
chronic
diseas
solid
organ
transplant
longterm
immunosuppress
treatment
recent
observ
reactiv
leishmania
infect
patient
receiv
methotrex
psoriasi
diagnos
viscer
leishmaniasi
vl
show
mucocutan
involv
analyz
epidemiolog
clinic
characterist
case
leishmaniasi
patient
psoriasi
found
review
literatur
patient
admit
infecti
diseas
unit
paolo
giaccon
hospit
palermo
painless
ulcer
lesion
onto
oral
mucosa
fig
two
nodular
ulcer
lesion
right
knee
anoth
one
instep
right
foot
appear
one
month
fig
patient
travel
outsid
itali
last
year
suffer
lowgrad
fever
last
month
consid
find
leishmaniasi
suspect
needl
aspir
oral
cutan
lesion
arrang
order
perform
microscopi
leishmaniapcr
posit
leishmania
laboratori
test
exhibit
wbc
hb
gdl
c
reactiv
protein
mgl
posit
serolog
leishmania
igg
posit
leishmaniapcr
test
peripher
blood
abdomin
us
examin
reveal
splenomegali
cm
methotrex
suspend
liposom
amphotericin
b
mgkg
per
day
day
follow
two
administr
two
week
later
start
cutan
mucos
lesion
improv
end
first
day
therapi
complet
vanish
two
administr
day
begin
treatment
leishmaniapcr
peripher
blood
day
therapi
neg
tabl
show
literatur
data
characterist
therapi
outcom
patient
psoriasi
leishmaniasi
leishmaniasi
vectorborn
chronic
infecti
diseas
caus
protozoa
genu
leishmania
transmit
human
bite
phlebotomin
sandfli
europ
mediterranean
countri
affect
area
leishmania
parasit
establish
chronic
intracellular
parasit
surviv
infect
person
lifetim
event
major
immun
defici
may
reactiv
site
latenc
leishmaniasi
present
spectrum
clinic
manifest
three
pattern
infect
describ
cutan
cl
mucos
mucocutan
ml
mcl
viscer
leishmaniasi
vl
infect
speci
leishmania
import
determin
clinic
manifest
host
immun
respons
crucial
determin
clinic
outcom
infect
today
nonhiv
relat
immunosuppress
condit
becom
increasingli
preval
mainli
better
medic
care
patient
chronic
ill
therapeut
use
immunosuppress
drug
field
rheumatolog
leishmaniasi
report
associ
use
variou
immunosuppress
drug
introduct
tumor
necrosi
factoralpha
antagonist
drug
receiv
much
attent
recent
sever
case
vl
report
rheumat
patient
antitnf
drug
psoriasi
chronic
inflammatori
autoimmun
diseas
affect
world
popul
character
aberr
hyperprolifer
keratinocyt
pathogenesi
psoriasi
complex
genet
suscept
environment
trigger
factor
overreact
local
innat
immun
respons
initi
inflamm
subsequ
involv
adapt
immun
respons
product
th
cytokin
chemokin
growth
factor
lead
epiderm
hyperplasia
recent
function
role
helper
cell
psoriasi
suggest
reduct
success
antitnf
treatment
also
known
lymphocyt
play
essenti
role
protect
intracellular
protozoa
success
clearanc
leishmania
strengthen
respons
view
could
argu
psoriasi
may
repres
protect
factor
leishmania
infect
inde
review
found
case
leishmaniasi
psoriat
subject
immunosuppress
therapi
biolog
agent
power
immunosuppress
drug
use
rheumat
patient
leishmania
infect
report
among
antitnfag
user
recent
maritati
et
al
found
higher
preval
subclin
leishmaniasi
patient
inflammatori
rheumat
diseas
receiv
biolog
drug
treat
immunosuppress
drug
howev
leishmaniasi
also
report
psoriat
patient
receiv
biolog
drug
occur
patient
tabl
diagnosi
cl
psoriat
patient
challeng
mimic
mani
infect
flareup
psoriasi
lead
ineffect
harm
chang
therapi
immunosuppress
therapi
caus
atyp
manifest
leishmaniasi
larg
lesion
spread
larg
cutan
area
associ
possibl
mucos
involv
ml
l
infantum
rare
sporad
describ
patient
receiv
power
immunosuppress
therapi
hivcoinfect
patient
mcl
mostli
observ
latin
america
l
braziliensi
account
case
l
panamensi
l
guyanensi
l
amazonensi
also
implic
rare
cutan
lesion
extend
area
skin
distant
mucosa
involv
case
two
lesion
foot
knee
associ
oral
lesion
context
impair
immun
also
advis
rule
vl
pcrleismania
peripher
blood
establish
appropri
therapi
intralesion
intraven
final
agreement
appropri
screen
leishmaniasi
immunosuppress
treatment
strategi
follow
diagnosi
leishmaniasi
rheumat
patient
take
immunosuppress
drug
molecular
method
highli
sensit
specif
tool
diagnosi
viscer
leishmaniasi
screen
leishmaniapcr
immunosuppress
patient
live
endem
area
could
use
identifi
patient
highest
risk
reactiv
specif
leishmaniasi
treatment
follow
suspens
immunosuppress
therapi
adopt
author
overal
even
treatment
respons
good
seen
immunocompet
popul
review
report
good
outcom
case
patient
remain
relapsefre
without
mainten
therapi
despit
ongo
use
immunosuppress
medic
conclus
physician
must
alert
possibl
develop
leishmaniasi
immunosuppress
rheumat
patient
adequ
screen
vl
incorpor
list
baselin
studi
carri
initi
biolog
therapi
least
endem
area
author
declar
conflict
interest
demonstr
sever
studi
journal
infect
herpesvirus
pose
increas
threat
human
health
accord
intern
committe
taxonomi
virus
ictv
equin
herpesvirus
ehv
belong
famili
herpesvirida
total
ehv
speci
type
determin
equin
viz
among
relev
herpesvirus
affect
equin
infect
associ
upper
respiratori
tract
diseas
infect
could
caus
abort
myeloenceph
preval
equin
contin
consider
econom
impact
hors
industri
china
number
equin
larg
reach
million
http
wwwstatsgovcntjsjzxfb
ehv
infect
equin
first
report
china
epidemiolog
investig
sinc
indic
ehv
preval
equin
popul
studi
provinc
mainland
china
seropreval
rang
vaccin
commonli
use
prevent
control
ehv
howev
china
develop
commerci
avail
ehv
vaccin
far
ehv
vaccin
limit
market
applic
potenti
china
current
due
lack
relev
knowledg
ehv
chines
hors
owner
alway
erron
identifi
common
pathogen
equin
respiratori
diseas
nt
realiz
potenti
threat
equin
health
reproduct
although
number
equin
china
larg
laborfarm
hors
best
knowledg
even
racehors
vaccin
ehv
vaccin
perform
mainland
china
consid
wide
distribut
high
preval
ehv
china
urgent
popular
knowledg
ehv
hors
owner
promot
market
applic
prospect
ehv
vaccin
china
veterinari
research
current
investig
equin
viru
includ
ehv
mainli
caus
chang
equin
histor
role
last
centuri
great
number
equin
use
militari
china
howev
one
militari
equin
farm
mainland
china
present
consid
import
econom
role
domest
anim
eg
pig
chicken
cattl
compar
equin
investig
equin
viru
includ
ehv
prioriti
relat
guid
polici
issu
chines
govern
though
epidemiolog
studi
ehv
china
limit
still
could
conclud
epidem
statu
ehv
complic
china
increas
difficulti
ehv
vaccin
develop
provinc
cocircul
equin
high
seropreval
total
strain
isol
tissu
sampl
abort
equin
fetus
farm
hors
northeast
china
asian
wild
hors
western
china
farm
hors
western
china
addit
novel
strain
isol
one
hors
seriou
respiratori
diseas
northern
china
recent
laboratori
firstli
determin
molecul
evinc
racehors
sothern
china
data
shown
howev
largescal
surveil
ehv
equin
necessari
fulli
understand
epidem
statu
ehv
china
could
establish
foundat
updat
composit
ehv
vaccin
develop
china
futur
countri
much
effort
made
develop
ehv
vaccin
modifiedl
inactiv
viru
vaccin
regist
sale
ehv
vaccin
develop
success
china
necessari
vaccin
suscept
equin
popul
ehv
vaccin
commerci
avail
countri
prevent
control
ehv
china
howev
welldesign
casecontrol
anim
challeng
studi
still
need
estim
protect
efficaci
differ
vaccin
field
preval
ehv
strain
china
author
declar
compet
interest
recent
review
articl
treatment
hepat
c
directlyact
antivir
daa
drug
make
numer
recommend
baselin
drug
resist
test
local
practic
perform
baselin
drug
resist
test
year
prior
public
guidelin
present
recent
retrospect
hcv
kinet
analysi
patient
chang
viral
load
respons
daa
therapi
studi
use
previous
compar
viral
suppress
respons
differ
hcv
genotyp
treatment
regimen
patient
mixtur
treatmentna
treatmentexperienc
includ
interferonbas
proteas
inhibitorbas
daabas
regimen
case
current
standard
care
hepat
hcv
patient
combin
direct
act
antivir
daa
three
differ
hcv
viral
protein
target
tabl
resist
associ
substitut
ra
hcv
genotyp
found
patient
cohort
baselin
drug
resist
test
viral
sequenc
perform
imperi
colleg
london
uk
patient
includ
mixtur
treatment
experienc
ie
interferonbas
proteas
inhibitorbas
recent
daabas
regimen
case
resist
associ
substitut
ra
hcv
genotyp
treatment
daa
cure
vast
major
hcvinfect
patient
oral
regimen
efficaci
patient
group
treatment
failur
current
affect
approxim
treat
patient
often
associ
select
resist
associ
substitut
ra
perform
hcv
drug
resist
test
retrospect
follow
treatment
failur
prospect
prior
treatment
cohort
hcv
genotyp
g
patient
march
viral
extract
pcr
sequenc
perform
imperi
colleg
use
qiagen
viral
rna
mini
kit
qiagen
qiagen
ltd
manchest
uk
inhous
pcr
sanger
sequenc
method
abi
prism
genet
analys
thermo
fischer
scientif
loughborough
uk
predict
hcv
genotyp
drug
sensit
deriv
algorithm
treatment
regimen
use
period
compli
contemporan
nh
rate
card
noncirrhot
compens
cirrhot
patient
ombparrit
da
r
elbgrz
r
glepib
gle
pib
cirrhot
patient
sofl
r
cirrhot
patient
sofvel
r
assess
impact
ra
across
hcv
rna
kinet
analys
viral
load
realtim
hcv
viral
load
abbott
abbott
molecular
uk
maidenhead
england
declin
rate
appli
linear
mix
regress
model
viral
load
assum
linear
declin
log
scale
time
use
sa
statist
softwar
sa
institut
inc
nc
usa
cohort
patient
n
hcv
ra
found
shown
tabl
hcv
rna
viral
load
declin
rate
found
similar
statist
differ
p
log
log
per
month
respect
fig
suggest
viral
load
declin
rate
similar
across
infect
despit
baselin
differ
viral
load
ra
profil
histori
previou
treatment
ie
interferonbas
older
proteas
inhibitorbas
recent
daa
regimen
result
demonstr
similar
hcv
rna
clearanc
efficaci
variou
daa
treatment
regimen
patient
cohort
although
studi
hcv
kinet
publish
usual
compar
multipl
hcv
genotyp
similar
studi
patient
infect
virus
andor
undergo
daa
treatment
retreat
combin
great
interest
read
report
zhang
et
al
concern
increas
suscept
pertussi
chines
adult
childbear
age
determin
compar
seropreval
studi
use
sampl
collect
author
describ
individu
ptigg
antibodi
indic
recent
infect
adult
year
age
subject
undetect
ptigg
antibodi
well
known
adolesc
adult
becom
reservoir
pertussi
import
sourc
transmiss
vulner
infant
bordetella
pertussi
commonli
associ
atyp
pneumonia
determin
hospit
children
sever
seropreval
studi
conduct
differ
region
china
indic
incid
pertussi
like
underestim
may
due
use
insensit
diagnost
present
diagnosi
pertussi
china
mainli
base
cultur
howev
cdc
world
health
organ
use
pcr
gold
standard
diagnosi
addit
cultur
oropharyng
nasopharyng
swab
obtain
inpati
age
day
year
age
clinic
suspicion
pertussi
enrol
march
februari
shenzhen
children
hospit
patient
younger
month
age
hospit
patient
includ
male
femal
sex
ratio
patient
recov
treatment
real
time
pcr
assay
target
ptxapr
use
detect
b
pertussi
sampl
test
posit
b
pertussi
rtpcr
result
indic
despit
vaccin
pertussi
remain
major
health
problem
china
sinc
preval
infect
b
pertussi
hospit
children
high
major
patient
admit
pneumonia
detect
rate
hospit
patient
lower
rate
report
earlier
shanghai
jinan
may
due
lower
number
sampl
collect
studi
due
use
serolog
cultur
method
overal
preval
rate
respect
howev
b
pertussi
infect
femal
patient
significantli
higher
male
patient
x
p
earlier
report
ecdc
haberl
et
al
may
point
genet
associ
suscept
b
pertussi
detect
rate
depend
age
patient
x
p
preval
decreas
age
newborn
infant
toddler
pre
schooler
fig
high
vulner
newborn
young
infant
b
pertussi
infect
may
relat
combin
insuffici
herd
immun
suboptim
protect
b
pertussi
infect
children
young
fulli
vaccin
sinc
vaccin
rate
infant
alreadi
difficult
improv
therefor
measur
must
consid
includ
booster
vaccin
preschool
age
vaccin
pregnanc
young
infant
mainli
care
mother
adult
import
caus
infect
b
pertussi
close
contact
parent
sibl
gener
b
pertussi
detect
often
season
chang
especi
late
summer
earli
autumn
hospit
children
number
b
pertussi
infect
increas
march
septemb
compar
month
fig
season
infect
rate
spring
summer
autumn
winter
respect
preval
winter
season
lower
statist
differ
season
x
p
studi
use
realtim
pcr
accur
method
detect
b
pertussi
detect
rate
may
significantli
lower
actual
level
oropharyng
sampl
patient
collect
instead
nasopharyng
sampl
pcr
target
gene
ptxapr
instead
present
highcopi
number
b
pertussi
wherea
ptxapr
singlecopi
target
howev
ptxapr
pcr
specif
detect
b
parapertussi
contribut
pertussi
case
mani
studi
shown
adolesc
adult
b
pertussi
infect
caus
chronic
cough
import
reservoir
transmiss
put
newborn
high
risk
matern
pertussi
immun
prevent
infant
pertussi
recent
shown
amirthalingam
et
al
vaccin
effect
infant
death
estim
diseas
incid
infant
month
age
remain
low
accord
result
vaccin
pregnant
women
adult
especi
close
contact
infant
young
children
may
help
prevent
pertussi
infant
young
children
china
author
declar
compet
interest
exist
studi
support
sanm
project
medicin
shenzhen
shenzhen
scienc
technolog
project
tang
colleagu
report
journal
experi
diseas
outbreak
began
decemb
wuhan
hubei
provinc
china
spread
addit
countri
februari
report
clinic
featur
outcom
first
two
case
diseas
caus
infect
unit
kingdom
uk
first
import
second
associ
probabl
persontoperson
transmiss
within
uk
public
health
manag
report
separ
index
case
enter
uk
hubei
provinc
china
initi
asymptomat
individu
yearold
femal
past
medic
histori
regular
medic
develop
symptom
fever
malais
accompani
sore
throat
dri
cough
travel
partner
report
infecti
contact
prior
travel
close
household
contact
index
case
resid
uk
develop
symptom
fever
follow
next
day
diffus
myalgia
dri
cough
patient
case
b
previous
fit
well
yearold
male
return
uk
hubei
provinc
case
b
promptli
sought
advic
via
nation
health
servic
nh
selfreferr
servic
nh
case
assess
possibl
risk
admit
region
infecti
diseas
unit
castl
hill
hospit
hull
univers
teach
hospit
isol
assess
diagnost
sampl
manag
separ
neg
pressur
cubicl
anteroom
nurs
medic
staff
don
person
protect
equip
ppe
recommend
public
health
england
phe
clinic
observ
patient
togeth
initi
blood
test
shown
tabl
fig
clinic
examin
find
unremark
initi
investig
reveal
mild
lymphopenia
elev
crp
mild
neutrophilia
case
b
period
fever
observ
case
b
admiss
repeat
blood
test
individu
demonstr
mild
acut
kidney
injuri
aki
serum
creatinin
aki
thought
like
due
dehydr
resolv
within
h
administr
intraven
infus
crystalloid
mlh
cxr
normal
empir
oral
antibiot
therapi
coamoxyclav
mg
po
td
administ
cover
possibl
secondari
bacteri
infect
subsequ
discontinu
symptom
resolv
case
case
b
admiss
pcr
test
nose
throat
swab
taken
daili
neg
onward
case
case
b
throat
swab
individu
neg
throughout
clinic
indic
use
experiment
antivir
therapi
patient
deisol
accord
current
phe
guidanc
base
complet
resolut
symptom
two
sequenti
neg
respiratori
pcr
test
least
h
apart
room
decontamin
hypochlorit
follow
uv
light
treatment
contact
individu
remain
asymptomat
throughout
day
incub
period
isol
precaut
close
famili
first
case
inform
clinician
care
suspect
confirm
case
uk
elsewher
reassuringli
ill
individu
rel
mild
shortliv
evid
parenchym
lung
diseas
reflect
normal
oxygen
absenc
radiolog
infiltr
latestag
deterior
report
case
seri
possibl
due
absenc
comorbid
experiment
antivir
therapeut
option
sever
diseas
consid
necessari
given
mild
clinic
natur
ill
clinic
ill
correl
presenc
viral
rna
upper
airway
sampl
fig
evid
prolong
asymptomat
shed
although
discord
nose
throat
sampl
case
b
highlight
need
sampl
area
reason
assum
sourc
infect
case
b
close
contact
symptomat
case
given
time
travel
china
onset
symptom
case
b
day
although
proven
base
assumpt
period
exposur
diseas
onset
appear
short
approxim
h
consist
recent
report
incub
period
cooccurr
respiratori
viral
infect
observ
case
b
rhinoviru
describ
context
http
wwwmedrxivorg
mani
respiratori
virus
spread
similar
rout
may
contribut
increas
symptomatolog
case
b
interestingli
partner
case
close
household
contact
remain
asymptomat
throughout
neg
test
shed
interest
investig
serolog
respons
individu
ascertain
evid
subclin
infect
isol
minimis
contact
use
appropri
ppe
cornerston
manag
high
consequ
respiratori
viral
infect
case
report
phe
recommend
ppe
follow
breech
ppe
nosocomi
transmiss
provid
reassur
healthcar
worker
manag
patient
suspect
uk
current
ppe
feasibl
effect
author
declar
known
compet
financi
interest
person
relationship
could
appear
influenc
work
report
paper
dear
editor
report
journal
elsewher
outbreak
atyp
pneumonia
caus
zoonot
novel
coronaviru
ongo
china
spread
world
feb
gmt
confirm
patient
death
infect
china
confirm
patient
death
affect
provinc
hubei
provinc
much
research
progress
made
dissect
evolut
origin
character
clinic
featur
outbreak
ongo
peopl
rais
grave
concern
futur
trajectori
outbreak
especi
given
work
school
time
alreadi
dramat
postpon
chines
lunar
new
year
holiday
schedul
jan
particular
precis
estim
potenti
total
number
infect
case
andor
confirm
case
highli
demand
earlier
studi
base
susceptibleexposedinfectiousrecov
metapopul
susceptibleinfectedrecovereddead
model
reveal
number
potenti
infect
case
basic
reproduct
number
tradit
epidemiolog
model
appar
requir
much
detail
data
analysi
explor
simpl
datadriven
boltzmann
functionbas
approach
estim
base
daili
cumul
number
confirm
case
note
ration
boltzmann
functionbas
regress
analysi
present
support
inform
si
file
decid
collect
data
initi
jan
feb
sever
typic
region
china
includ
center
outbreak
ie
wuhan
citi
hubei
provinc
four
affect
provinc
ie
guangdong
zhejiang
henan
hunan
major
citi
china
ie
beij
shanghai
guangzhou
shenzhen
data
analysi
feb
number
new
confirm
case
feb
hubei
provinc
wuhan
citi
suddenli
increas
respect
confirm
clinic
featur
note
number
confirm
case
releas
feb
count
accord
result
viral
nucleic
acid
detect
rather
refer
clinic
featur
thu
arbitrarili
distribut
suddenli
ad
case
report
cumul
number
confirm
case
jan
feb
hubei
provinc
fix
factor
refer
tabl
assum
linearli
accumul
day
forth
data
wuhan
citi
regress
analys
indic
set
data
well
fit
boltzmann
function
r
valu
close
fig
b
tabl
potenti
total
number
confirm
case
mainland
china
hubei
provinc
wuhan
citi
provinc
estim
respect
provinc
guangdong
zhejiang
henan
hunan
respect
tabl
beij
shanghai
guangzhou
shenzhen
respect
addit
estim
key
date
number
daili
new
confirm
case
lower
potenti
total
number
defin
us
subject
refer
tabl
analys
perform
assum
releas
data
confirm
case
precis
howev
health
commiss
state
administr
tradit
chines
medicin
academi
chines
medic
scienc
provinc
citi
well
armi
fig
huoshenshan
hospit
special
hospit
establish
wuhan
staff
sanatorium
patient
confirm
coronaviru
pneumonia
admit
hospit
total
bed
includ
intens
care
unit
ordinari
care
unit
laboratori
radiolog
auxiliari
depart
accord
nation
health
commiss
peopl
republ
china
relat
design
scheme
institut
complet
januari
construct
hospit
began
januari
hospit
complet
put
use
februari
chines
peopl
liber
armi
transfer
medic
personnel
undertak
task
help
peopl
infect
viru
firmli
believ
chines
medic
personnel
peopl
throughout
countri
work
togeth
win
defens
battl
one
heart
one
mind
